A5394

I'm Interested!

Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with Both Chronic Hepatitis B and HIV

Sex at Birth: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase II
Conditions Being Studied: Hepatitis B

Study Purpose

The purpose of this study is to see if the experimental drug Selgantolimod (SLGN) is safe and tolerable for people who have chronic hepatitis B (CHB) and HIV, and whether it reduces the amount of hepatitis B virus in people with CHB and HIV.

Who Can Participate

Age: 18-70

Principal Investigator
George Yendewa MD MPH

Department/Division
Infectious Disease (Medicine)

Locations

UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: STUDY20220958
StudyID: 2022-01062
ClinicalTrials.gov: NCT05551273

I'm Interested!

Fill out our online form

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422